The first hurdle for a woman seeking treatment for Polycystic Ovary Syndrome (PCOS) in India is often not the diagnosis, but the quality of care that follows. It is a condition of frustrating contradictions, affecting an estimated 110 million women in the country, yet frequently met with dismissive, one-size-fits-all advice from a healthcare system ill-equipped for chronic, multifaceted management [YourStory, July 2021]. This gap between patient need and clinical reality is where Veera Health has planted its flag, building a digital clinic that wraps gynecologists, nutritionists, and mental health coaches around a single patient via a subscription-based app.
Founded in 2020 by sisters Shobhita and Shashwata Narain, Veera’s model is a direct response to their own experience navigating PCOS. Shobhita Narain has spoken publicly about confronting intense mood swings, facial hair, and weight gain, only to be told by specialists to simply “lose weight” or “get married” [Mint]. That firsthand frustration with a broken pathway is now the company’s foundational thesis: that effective PCOS care requires continuous, multidisciplinary support, not episodic doctor visits.
A vertical wedge into chronic women’s health
Veera’s strategy is a classic vertical wedge. Instead of building a broad primary care platform, it has started with a single, high-prevalence condition. PCOS is a hormonal disorder with symptoms spanning reproductive health, metabolic function, and mental well-being, making it notoriously difficult to manage through a single specialist. Veera’s program, delivered through its app, combines consultations with gynecologists, customized nutrition plans, lifestyle coaching, and ongoing monitoring for a subscription fee [YourStory, July 2021].
The company’s clinical differentiation rests on this coordinated, evidence-based approach. It claims peer-reviewed outcomes for its digital therapeutics platform, and positions itself as the only women’s hormonal health company published in the American Society for Reproductive Medicine [Veera Health website, retrieved 2026]. In a consumer study, Veera reported that 97% of women saw improvement in at least one PCOS symptom [Instagram].
The team, traction, and tailwinds
Veera has raised approximately $4.13 million in total funding, including a $3 million seed round in July 2021 led by Global Founders Capital, with participation from Surge and Y Combinator [YourStory, July 2021][CB Insights]. The company reports a team of 59 employees, suggesting significant investment in clinical operations and care delivery alongside technology [Built In Mumbai].
| Metric | Value |
|---|---|
| 2021 Seed | $3M |
| Total Raised | $4.13M |
Navigating the non-physician founder question
A recurring question for any digital health startup is the clinical credentials of its leadership. The Narain sisters are not physicians, a fact noted in early coverage [YourStory, July 2021]. Veera’s answer has been to build clinical credibility through external validation and by embedding licensed professionals into its care model. The publication of its methodology in a reproductive medicine journal and the involvement of doctors from the University of Pennsylvania in a study are deliberate moves to anchor its services in established medical science [Scribd].
What comes after the wedge
The next twelve months for Veera will likely focus on proving the unit economics of its PCOS program and deepening its clinical evidence. The company is well-positioned to expand its service offerings within women’s hormonal health, using PCOS as an entry point to address related conditions like endometriosis or perimenopause. For the estimated 110 million women in India with PCOS, the standard of care today is often fragmented and unsatisfactory. Veera Health is betting that a coordinated, app-based clinic can not only fill those gaps but become the new default for managing this chronic condition.